BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 2021. [PMID: 34729652 DOI: 10.1007/s10067-021-05973-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Misra DP, Rathore U, Mishra P, Singh K, Thakare DR, Behera MR, Jain N, Ora M, Bhadauria DS, Gambhir S, Kumar S, Agarwal V. Comparison of Presentation and Prognosis of Takayasu Arteritis with or without Stroke or Transient Ischemic Attack—A Retrospective Cohort Study. Life 2022;12:1904. [DOI: 10.3390/life12111904] [Reference Citation Analysis]
2 Henes JC, Saur S. Diagnostik und Therapie der Großgefäßvaskulitiden – Wo stehen wir aktuell? Aktuelle Rheumatologie 2022. [DOI: 10.1055/a-1931-3989] [Reference Citation Analysis]
3 Misra DP, Jain N, Ora M, Singh K, Agarwal V, Sharma A. Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis. Diagnostics (Basel) 2022;12:2565. [PMID: 36292253 DOI: 10.3390/diagnostics12102565] [Reference Citation Analysis]
4 Misra DP, Pande G, Agarwal V. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box. Clin Rheumatol 2022. [PMID: 36264400 DOI: 10.1007/s10067-022-06415-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Misra DP, Rathore U, Kopp CR, Patro P, Agarwal V, Sharma A. Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol 2022. [PMID: 35927524 DOI: 10.1007/s10067-022-06318-5] [Reference Citation Analysis]
6 Watanabe R, Hashimoto M. Perspectives of JAK Inhibitors for Large Vessel Vasculitis. Front Immunol 2022;13:881705. [PMID: 35432355 DOI: 10.3389/fimmu.2022.881705] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Watanabe R, Hashimoto M. Aging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders. Front Aging Neurosci 2022;14:843305. [DOI: 10.3389/fnagi.2022.843305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Singh K, Rathore U, Rai MK, Behera MR, Jain N, Ora M, Bhadauria D, Sharma S, Pande G, Gambhir S, Nath A, Kumar S, Sharma A, Agarwal V, Misra DP. Novel Th17 Lymphocyte Populations, Th17.1 and PD1+Th17, are Increased in Takayasu Arteritis, and Both Th17 and Th17.1 Sub-Populations Associate with Active Disease. JIR 2022;Volume 15:1521-41. [DOI: 10.2147/jir.s355881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
9 Koster MJ, Crowson CS, Giblon RE, Jaquith JM, Duarte-García A, Matteson EL, Weyand CM, Warrington KJ. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis 2022:annrheumdis-2021-221961. [PMID: 35190385 DOI: 10.1136/annrheumdis-2021-221961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
10 Singla S, Kalani K, Ban A. Co-existing ulcerative colitis and takayasu arteritis: A case-based review. Indian J Rheumatol 2022;0:0. [DOI: 10.4103/injr.injr_290_21] [Reference Citation Analysis]